Coagulation factor XI

Coagulation factor XI Informations sur la molécule

Nom anglais	Coagulation factor XI	Nombre de médicaments commercialisés	2
Nombre de médicaments cliniques	30	Alias de la cible	EC 3.4.21，EC:3.4.21.27，FXI，F11，PTA，Coagulation Factor XI，Plasma Thromboplastin Antecedent，EC 3.4.21.27，Factor XI，Coagualtion Factor XI
Phase de R&D la plus avancée	Approved

Nom anglais	Coagulation factor XI
Alias de la cible	EC 3.4.21，EC:3.4.21.27，FXI，F11，PTA，Coagulation Factor XI，Plasma Thromboplastin Antecedent，EC 3.4.21.27，Factor XI，Coagualtion Factor XI
Nombre de médicaments commercialisés	2
Nombre de médicaments cliniques	30
Phase de R&D la plus avancée	Approved

Coagulation factor XI Liste de produits

Attribut
Protein (2)
Bibliothèque de produits
En ligne (2)
Espèces
Human (1)Rhesus macaque (1)
Étiquette
His Tag (2)
Marqueur
Unconjugated (2)

Numéro de produit	Espèces	Système d'expression	Description du produit	Structure protéique	Pureté	Caractéristiques	Pré-commande/Commande
FXI-H52H5	Human	HEK293	Human Coagulation factor XI / FXI Protein, His Tag (active enzyme)				Ajouter au panier
FXI-C52H3	Rhesus macaque	HEK293	Rhesus macaque Coagulation factor XI Protein, His Tag (Pro-form)				Ajouter au panier

Quantité totale2

Coagulation factor XIContexte de la molécule

This protein is present in plasma as a zymogen, which is a unique plasma coagulation enzyme because it exists as a homodimer consisting of two identical polypeptide chains linked by disulfide bonds. During activation of the plasma factor XI, an internal peptide bond is cleaved by factor XIIa (or XII) in each of the two chains, resulting in activated factor XIa, a serine protease composed of two heavy and two light chains held together by disulfide bonds. This activated plasma factor XI triggers the middle phase of the intrisic pathway of blood coagulation by activating factor IX. Defects in this factor lead to Rosenthal syndrome, a blood coagulation abnormality

Coagulation factor XIAlias de la molécule

Coagulation factor XI,FXI,PTA,F11

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
Asundexian	BAY-2433334	Phase 3 Clinical	Bayer AG	Atrial Fibrillation; Embolism; Hepatic Insufficiency; Ischemic Attack, Transient; Ischemic Stroke; Myocardial Infarction; Stroke; Thromboembolism	Details
Cenvacibart	REGN7508	Phase 3 Clinical	Regeneron Pharmaceuticals Inc	Atrial Fibrillation; Peripheral Arterial Disease; Thrombosis; Venous Thromboembolism	Details
Milvexian	BMS-986177; JNJ-70033093; JNJ-3093	Phase 3 Clinical	Bristol-Myers Squibb Company	Acute Coronary Syndrome; Atrial Fibrillation; Contraception; Coronary Thrombosis; Embolism; Ischemic Attack, Transient; Ischemic Stroke; Kidney Failure, Chronic; Renal Insufficiency; Stroke; Thromboembolism; Thrombosis	Details
SHR-2004	SHR-2004	Phase 3 Clinical	Beijing Suncadia Medicine Co Ltd	Arterial Thromboembolism; Atrial Fibrillation; Dyslipidemias; Thromboembolism; Thrombosis; Venous Thromboembolism; Venous Thrombosis	Details
Amrecibart	REGN-9933	Phase 3 Clinical	Regeneron Pharmaceuticals Inc	Atrial Fibrillation; Peripheral Arterial Disease; Venous Thromboembolism	Details
Abelacimab	MAA-868; NOV-12	Phase 3 Clinical	Novartis Pharma Ag	Atrial Fibrillation; Embolism; Neoplasms; Pulmonary Embolism; Stroke; Thromboembolism; Venous Thromboembolism; Venous Thrombosis	Details
EP-7041	EP-7041; HSK-36273	Phase 2 Clinical	Exithera Pharmaceuticals Inc	Blood Coagulation Disorders; Coronavirus Disease 2019 (COVID-19); Kidney Diseases; Thrombocytopenia; Thromboembolism; Thrombosis	Details
Osocimab	BAY-1213790	Phase 2 Clinical	Bayer AG	Kidney Diseases; Kidney Failure, Chronic; Thromboembolism	Details
IONIS-FXIRX	ISIS-404071; BAY-2306001; ISIS-FXIRX; FXI-ASO; IONIS-FXIRX; ISIS-416858	Phase 2 Clinical	Ionis Pharmaceuticals Inc	Thrombosis; Venous Thromboembolism	Details
MK-2060	MK-2060	Phase 2 Clinical	Merck Sharp & Dohme Corp	Kidney Diseases; Kidney Failure, Chronic; Thromboembolism; Thrombosis	Details
SRSD-107	SRSD-107; SRSD107	Phase 2 Clinical	Sirius Therapeutics Inc	Arterial Thromboembolism; Cardiovascular Diseases; Coronary Artery Disease; Coronary Disease; Peripheral Arterial Disease; Thromboembolism; Thrombosis; Venous Thromboembolism	Details
RBD-4059	RBD-4059; RBD4059; SR059; SR-059	Phase 2 Clinical	Suzhou Ribo Life Science Co Ltd	Coronary Artery Disease; Coronary Disease; Kidney Failure, Chronic; Venous Thrombosis	Details
KN-060	KN-060; KN060	Phase 2 Clinical	Suzhou Alphamab Co Ltd	Essential Hypertension; Hypertension; Kidney Failure, Chronic; Obesity; Overweight; Thromboembolism	Details
Ir-CPI	BIOX-101; Ir-CPI	Phase 2 Clinical	Free University Of Brussels	Cerebral Hemorrhage	Details
Fesomersen	ION-957943; IONIS-FXI-LRx; BAY-2976217	Phase 2 Clinical	Ionis Pharmaceuticals Inc	Nephrosis; Thromboembolism	Details
ONO-7269	ONO-7269	Phase 1 Clinical	Ono Pharmaceutical Co Ltd	Cerebral Infarction	Details
BAY-1831865	AB-012; BAY-1831865	Phase 1 Clinical	Aronora Inc	Thrombosis	Details
A-336	A336; A-336	Phase 1 Clinical	Klus Pharma	Thromboembolism	Details
A-186	A-186	Phase 1 Clinical	Sichuan Kelun Pharmaceutical Co Ltd	Thromboembolism	Details
BMS-262084	BMS-262084	Phase 1 Clinical	Bristol-Myers Squibb Company	Thrombosis	Details
ADX-626	ADX-626	Phase 1 Clinical	ADARx Pharmaceuticals Inc	Thrombosis	Details
SBK-013	SBK013; SBK-013	Phase 1 Clinical	Chengdu Shibeikang Biomedical Technology Co Ltd	Arterial Thromboembolism; Thromboembolism; Venous Thromboembolism	Details
XH-S002	XH-S002; XHS002	Phase 1 Clinical		Ischemic Attack, Transient; Stroke	Details
BMS-986209	BMS-986209	Phase 1 Clinical	Bristol-Myers Squibb Company		Details
NIP-003	NIP003; NIP-003; CRB4101; CRB-4101	Phase 1 Clinical	National Institutes Of Pharmaceutical Research And Development Co Ltd	Thromboembolism; Venous Thromboembolism; Venous Thrombosis	Details
Factor XIa Inhibitor (Bayer)	Factor XIa Inhibitor (Bayer)	Phase 1 Clinical	Bayer AG	Blood Coagulation Disorders	Details
SKB-336	SKB-336	Phase 1 Clinical	Sichuan Kelun-Biotech Biopharmaceutical Co Ltd	Embolism; Thromboembolism	Details
SAL-0104	SAL-0104; SAL0104	Phase 1 Clinical	Suzhou Genemen Biotech Co Ltd	Cardiovascular Diseases; Embolism; Ischemic Attack, Transient; Myocardial Infarction; Stroke; Thrombosis; Venous Thromboembolism; Venous Thrombosis	Details
STP122G	STP-122G; STP122G	Phase 1 Clinical	Sirnaomics Biopharmaceuticals (Suzhou) Co Ltd	Embolism and Thrombosis	Details
SHR2285	SHR-2285	Phase 1 Clinical	Jiangsu Hengrui Medicine Co Ltd	Embolism; Thromboembolism; Thrombosis; Venous Thromboembolism	Details

Informations sur les médicaments commercialisés

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Plus ancien nom de marque	Pays d'approbation le plus ancien	Indication la plus ancienne	Société d'approbation la plus ancienne	Date d'approbation la plus ancienne	Indication	Essai clinique
Factor XI concentrate (factor XI deficiency), CSL Behring		Approved	Csl Behring Llc		Australia	Factor XI Deficiency	Csl Behring Llc	2014-07-01	Factor XI Deficiency	Details
Human coagulation Factor XI (LFB)		Approved	Lfb Biotechnologies Sas	Hemoleven	EU	Factor XI Deficiency	Lfb Biotechnologies Sas	1999-07-01	Factor XI Deficiency	Details